Company intelligence / Profile preview
EndoCell Therapeutics
- Ownership
- Private
- Development stage
- Other
Overview
EndoCell Therapeutics is a Swiss biotechnology company dedicated to developing a functional cure for Type 1 Diabetes through innovative cell therapy. The company's proprietary platform engineers non-pancreatic human cells to become glucose-responsive, insulin-secreting "EndoCells." By bypassing the need for scarce donor islets and potentially reducing the requirement for chronic immunosuppression, EndoCell aims to provide a scalable and effective treatment for insulin-dependent patients. The company is a spin-off from the University of Geneva and is currently advancing its lead program through pre-clinical validation.
- Therapeutic areas
- Endocrinology
- Modalities
- Cell therapyGene-edited cell therapy
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on EndoCell Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EndoCell Therapeutics.